본문 바로가기

카테고리 없음

Atopic Dermatitis Market Analysis and Market Forecast 2030

Atopic Dermatitis market

Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood with changing severity over the years. In children under one year of age, much of the body may be affected. As children grow, the back of the knees and front of the elbows are the most common areas affected. In adults, the hands and feet are the most commonly affected areas. Scratching worsens symptoms, and affected people have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma.

 

As per the National Eczema Association 2019, Atopic Dermatitis (AD) is the most common type of eczema. More than 18 million American adults have Atopic Dermatitis which often appears as a red, itchy rash typically on the cheeks, arms and legs.

 

The prevalence of childhood Atopic Dermatitis ranged from 15% to 30%, while adult Atopic Dermatitis prevalence ranges from 2% to 10% in industrialized countries.

 

As per DelveInsight estimates, higher prevalent population of uncontrolled Atopic Dermatitis is observed in the United States as compared to EU5 countries and Japan.

 

Atopic dermatitis typically begins in childhood, usually in the first six months of a baby's life. Even though it's a common form of eczema, it's also severe and long-lasting.


According to the DelveInsight estimates, a large number of people are suffering from mild Atopic Dermatitis. In the United States, the prevalent population of Atopic Dermatitis was found to be 19,460,609 in 2017.

 

Some of the emerging therapies in Atopic Dermatitis market include PF-04965842, ZPL389, DS-2741A, Upadacitinib (ABT-494) and others. 

Key companies in the Atopic Dermatitis market include Pfizer, Novartis Pharmaceuticals, Daiichi Sankyo, AbbVie, PurGenesis Technologies Inc and others. 

 

For more details visit: https://www.delveinsight.com/report-store/atopic-dermatitis-ad-market

 

#Psoriasis #AtopicDermatitis #Dermatology #SkinDisorders #Atopic